Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK3 | P27361 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | SRC | P12931 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837205 | 0.90 | MAPK3 (0.57) | MAPK3MAPK1KMOALDH1A1CYP1A2 | |
| SCHEMBL17837239 | 0.90 | MAPK3 (0.58) | MAPK3MAPK1 | |
| SCHEMBL21965940 | 0.87 | MAPK1 (0.78) | MAPK3MAPK1EIF2AK2PIK3CAABL1 | |
| SCHEMBL17856223 | 0.84 | MAPK3 (0.49) | MAPK3MAPK1BACE1BACE2 | |
| SCHEMBL17837248 | 0.83 | MAPK1 (0.53) | MAPK3MAPK1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL21075869 | 0.82 | MAPK3 (0.71) | MAPK3MAPK1EIF2AK2PIK3CAABL1 | |
| Temuterkib SCHEMBL17837273 | 0.82 | MAPK1 (1.00) | MAPK3MAPK1ABL1BCRMKNK1 | |
| SCHEMBL17837204 | 0.82 | MAPK1 (0.53) | MAPK3MAPK1FGFR1SRCMCHR1 | |
| SCHEMBL17837172 | 0.81 | MAPK3 (0.72) | MAPK3MAPK1ABL1BCR | |
| SCHEMBL17837173 | 0.81 | MAPK1 (0.52) | MAPK3MAPK1FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-RE48635-E1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200306254-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200306254-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | LILLY CO ELI (US) | 2020-10-01 | — | — | US | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3478292-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | Eli Lilly and Company (US) | 2019-05-08 | — | — | EP | disclosed |
| WO-2018005234-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | ELI LILLY AND COMPANY (US) | 2018-01-04 | — | — | WO | disclosed |
| EP-3237423-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306254-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | KRAS, MAPKAPK2, MAPK1 | MAPK3 6/4885MAPK1 3/4885KMO 4489/4885 |
| US-20160375030-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK3 3/4885MAPK1 2/4885KMO 3415/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK3 3/4885MAPK1 2/4885KMO 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.